182 related articles for article (PubMed ID: 33946824)
1. RRx-001 Increases Erythrocyte Preferential Adhesion to the Tumor Vasculature.
Jani VP; Asaro R; Oronsky B; Cabrales P
Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33946824
[TBL] [Abstract][Full Text] [Related]
2. RRx-001, an epigenetic-based radio- and chemosensitizer, has vascular normalizing effects on SCCVII and U87 tumors.
Oronsky B; Scicinski J; Cabrales P; Minchinton A
Clin Epigenetics; 2016; 8():53. PubMed ID: 27175220
[TBL] [Abstract][Full Text] [Related]
3. A look inside the mechanistic black box: Are red blood cells the critical effectors of RRx-001 cytotoxicity?
Cabrales P; Scicinski J; Reid T; Kuypers F; Larkin S; Fens M; Oronsky A; Oronsky B
Med Oncol; 2016 Jul; 33(7):63. PubMed ID: 27229330
[TBL] [Abstract][Full Text] [Related]
4. From METS to malaria: RRx-001, a multi-faceted anticancer agent with activity in cerebral malaria.
Yalcin O; Oronsky B; Carvalho LJ; Kuypers FA; Scicinski J; Cabrales P
Malar J; 2015 May; 14():218. PubMed ID: 26017006
[TBL] [Abstract][Full Text] [Related]
5. A novel hypoxia-selective epigenetic agent RRx-001 triggers apoptosis and overcomes drug resistance in multiple myeloma cells.
Das DS; Ray A; Das A; Song Y; Tian Z; Oronsky B; Richardson P; Scicinski J; Chauhan D; Anderson KC
Leukemia; 2016 Nov; 30(11):2187-2197. PubMed ID: 27118403
[TBL] [Abstract][Full Text] [Related]
6. Epigenetic effects of RRx-001: a possible unifying mechanism of anticancer activity.
Zhao H; Ning S; Scicinski J; Oronsky B; Knox SJ; Peehl DM
Oncotarget; 2015 Dec; 6(41):43172-81. PubMed ID: 26657731
[TBL] [Abstract][Full Text] [Related]
7. Nitrite may serve as a combination partner and a biomarker for the anti-cancer activity of RRx-001.
Cirrik S; Ugurel E; Aksu AC; Oronsky B; Cabrales P; Yalcin O
Biorheology; 2019; 56(4):221-235. PubMed ID: 31640080
[TBL] [Abstract][Full Text] [Related]
8. RRx-001: a systemically non-toxic M2-to-M1 macrophage stimulating and prosensitizing agent in Phase II clinical trials.
Oronsky B; Paulmurugan R; Foygel K; Scicinski J; Knox SJ; Peehl D; Zhao H; Ning S; Cabrales P; Summers TA; Reid TR; Fitch WL; Kim MM; Trepel JB; Lee MJ; Kesari S; Abrouk ND; Day RM; Oronsky A; Ray CM; Carter CA
Expert Opin Investig Drugs; 2017 Jan; 26(1):109-119. PubMed ID: 27935336
[TBL] [Abstract][Full Text] [Related]
9. RRx-001, a novel clinical-stage chemosensitizer, radiosensitizer, and immunosensitizer, inhibits glucose 6-phosphate dehydrogenase in human tumor cells.
Oronsky B; Scicinski J; Reid T; Oronsky A; Carter C; Oronsky N; Cabrales P
Discov Med; 2016 Apr; 21(116):251-65. PubMed ID: 27232511
[TBL] [Abstract][Full Text] [Related]
10. Variable adhesion of different red blood cell products to activated vascular endothelium under flow conditions.
Anniss AM; Sparrow RL
Am J Hematol; 2007 Jun; 82(6):439-45. PubMed ID: 17133424
[TBL] [Abstract][Full Text] [Related]
11. RRx-001 protects normal tissues but not tumors via Nrf2 induction and Bcl-2 inhibition.
Oronsky B; Scribner C; Aggarwal R; Cabrales P
J Cancer Res Clin Oncol; 2019 Aug; 145(8):2045-2050. PubMed ID: 31250159
[TBL] [Abstract][Full Text] [Related]
12. The immunomodulatory anticancer agent, RRx-001, induces an interferon response through epigenetic induction of viral mimicry.
Zhao H; Ning S; Nolley R; Scicinski J; Oronsky B; Knox SJ; Peehl DM
Clin Epigenetics; 2017; 9():4. PubMed ID: 28149332
[TBL] [Abstract][Full Text] [Related]
13. Cardioprotective Effect of Phase 3 Clinical Anticancer Agent, RRx-001, in Doxorubicin-Induced Acute Cardiotoxicity in Mice.
Oronsky B; Ao-Ieong ESY; Yalcin O; Carter CA; Cabrales P
Mol Pharm; 2019 Jul; 16(7):2929-2934. PubMed ID: 31038318
[TBL] [Abstract][Full Text] [Related]
14. RRx-001 protects against cisplatin-induced toxicities.
Oronsky B; Reid TR; Larson C; Carter CA; Brzezniak CE; Oronsky A; Cabrales P
J Cancer Res Clin Oncol; 2017 Sep; 143(9):1671-1677. PubMed ID: 28417195
[TBL] [Abstract][Full Text] [Related]
15. Rockets, radiosensitizers, and RRx-001: an origin story part I.
Oronsky B; Scicinski J; Ning S; Peehl D; Oronsky A; Cabrales P; Bednarski M; Knox S
Discov Med; 2016 Mar; 21(115):173-80. PubMed ID: 27115167
[TBL] [Abstract][Full Text] [Related]
16. Modulation of RAGE expression influences the adhesion of red blood cells from diabetic patients.
Wautier MP; Khodabandehlou T; Le Dévéhat C; Wautier JL
Clin Hemorheol Microcirc; 2006; 35(3):379-86. PubMed ID: 16899960
[TBL] [Abstract][Full Text] [Related]
17. Platelet inhibitory effects of the Phase 3 anticancer and normal tissue cytoprotective agent, RRx-001.
Oronsky B; Oronsky N; Cabrales P
J Cell Mol Med; 2018 Oct; 22(10):5076-5082. PubMed ID: 30010241
[TBL] [Abstract][Full Text] [Related]
18. Discovery of RRx-001, a Myc and CD47 Downregulating Small Molecule with Tumor Targeted Cytotoxicity and Healthy Tissue Cytoprotective Properties in Clinical Development.
Oronsky B; Guo X; Wang X; Cabrales P; Sher D; Cannizzo L; Wardle B; Abrouk N; Lybeck M; Caroen S; Oronsky A; Reid TR
J Med Chem; 2021 Jun; 64(11):7261-7271. PubMed ID: 34043360
[TBL] [Abstract][Full Text] [Related]
19. Targeting tumor hypoxia with the epigenetic anticancer agent, RRx-001: a superagonist of nitric oxide generation.
Fens MH; Cabrales P; Scicinski J; Larkin SK; Suh JH; Kuypers FA; Oronsky N; Lybeck M; Oronsky A; Oronsky B
Med Oncol; 2016 Aug; 33(8):85. PubMed ID: 27377482
[TBL] [Abstract][Full Text] [Related]
20. Prior exposure of endothelial cells to hydroxycarbamide alters the flow dynamics and adhesion of sickle red blood cells.
Verger E; Schoëvaërt D; Carrivain P; Victor JM; Lapouméroulie C; Elion J
Clin Hemorheol Microcirc; 2014; 57(1):9-22. PubMed ID: 24002118
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]